Pulmonary artery hypertension in adults: Old disease, new medication

This review article aims to give an update on newer pharmacological and interventional strategies existing for the treatment of pulmonary artery hypertension in adults. Besides conservative therapies such as anticoagulants and diuretics, the current paradigm targets the three main biologic pathways that are critical for its pathogenesis i.e. endothelin receptor antagonists (Bosentan, Ambrisentan, Macitentan), phosphodiesterase 5 inhibitors (Sildenafil, tadalafil) and prostacyclin up regulation (Epoprostenol, Iloprost, Treprostinil). Currently, available drugs have completely changed the dismal prognosis for pulmonary artery hypertension patients to better outcome.